André Lescarbeau

Discovery of a Potent and Orally Active Hedgehog Pathway Antagonist (IPI-926)

Martin Tremblay, André Lescarbeau, Michael J. Grogan et al. · Journal of Medicinal Chemistry · 2009 · 251 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate

Catherine A. Evans, Tao Liu, André Lescarbeau et al. · ACS Medicinal Chemistry Letters · 2016 · 151 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +11

Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia

Andreas Varkaris, Ermira Pazolli, Hakan Günaydin et al. · Cancer Discovery · 2023 · 90 citations · Full text

Life Sciences, Medicinal Chemistry, Oncology +17

Synthetic Silvestrol Analogues as Potent and Selective Protein Synthesis Inhibitors

Tao Liu, Somarajan Nair, André Lescarbeau et al. · Journal of Medicinal Chemistry · 2012 · 80 citations · Full text

Life Sciences, Cancer Biology, Molecular Biology +13

Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2

Heike Schönherr, Pelin Ayaz, Alexander M. Taylor et al. · Proceedings of the National Academy of Sciences · 2024 · 66 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14